Form 4 Filing by Christopher Martell for Candel Therapeutics, Inc.

Christopher Martell, a director at Candel Therapeutics, Inc. (CADL), acquired 32,000 stock options on June 23, 2026. These options, with an exercise price of $9.08, are subject to time-based vesting. The shares underlying the options will vest on the earlier of June 23, 2027, or the next Annual Meeting of Stockholders, provided Martell continues to serve as a director. The options expire on June 23, 2036. This transaction is reported on Form 4.